AR005811A1 - MODIFIED NATURAL COMPLEMENTARY VIA PROTEIN, SEQUENCE AND DNA CONSTRUCTION THAT CODES IT, CONJUGATED AND PHARMACEUTICAL FORMULATION THAT UNDERSTANDS IT, ITS USE AND METHOD TO REDUCE IT IN A MAMMAL. - Google Patents
MODIFIED NATURAL COMPLEMENTARY VIA PROTEIN, SEQUENCE AND DNA CONSTRUCTION THAT CODES IT, CONJUGATED AND PHARMACEUTICAL FORMULATION THAT UNDERSTANDS IT, ITS USE AND METHOD TO REDUCE IT IN A MAMMAL.Info
- Publication number
- AR005811A1 AR005811A1 ARP970100576A ARP970100576A AR005811A1 AR 005811 A1 AR005811 A1 AR 005811A1 AR P970100576 A ARP970100576 A AR P970100576A AR P970100576 A ARP970100576 A AR P970100576A AR 005811 A1 AR005811 A1 AR 005811A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- pharmaceutical formulation
- understands
- mammal
- conjugated
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 7
- 102000004169 proteins and genes Human genes 0.000 title abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 title 1
- 230000000295 complement effect Effects 0.000 title 1
- 238000010276 construction Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 abstract 1
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 abstract 1
- 101000901154 Homo sapiens Complement C3 Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 102000057770 human C3 Human genes 0.000 abstract 1
- 102000035118 modified proteins Human genes 0.000 abstract 1
- 108091005573 modified proteins Proteins 0.000 abstract 1
- 230000009870 specific binding Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Landscapes
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una proteína de vía de complemento natural modificada de tal forma que la proteína es capaz de formar una convertasa C3 estable. Preferentemente, laproteína modificada es una proteina C3 humana modificada. Las secuencias de ADN que codifican aestas proteínas también se proveen, junto con lasconstrucciones de ADN. También se describen los conjugados que comprende a esta proteína y a una parte de enlace específico, por ejemplo, un anticuerpo, asícomo una formulación farmacéutica quecompren de dicha proteína, usos así como de esta proteína y/o conjugado en la terapia de mamíferos.A natural complement pathway protein modified such that the protein is capable of forming a stable C3 convertase. Preferably, the modified protein is a modified human C3 protein. DNA sequences encoding these proteins are also provided, along with DNA constructs. Conjugates comprising this protein and a specific binding part are also described, for example, an antibody, as well as a pharmaceutical formulation that they purchase of said protein, uses as well as this protein and / or conjugate in mammalian therapy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP970100576A AR005811A1 (en) | 1997-02-13 | 1997-02-13 | MODIFIED NATURAL COMPLEMENTARY VIA PROTEIN, SEQUENCE AND DNA CONSTRUCTION THAT CODES IT, CONJUGATED AND PHARMACEUTICAL FORMULATION THAT UNDERSTANDS IT, ITS USE AND METHOD TO REDUCE IT IN A MAMMAL. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP970100576A AR005811A1 (en) | 1997-02-13 | 1997-02-13 | MODIFIED NATURAL COMPLEMENTARY VIA PROTEIN, SEQUENCE AND DNA CONSTRUCTION THAT CODES IT, CONJUGATED AND PHARMACEUTICAL FORMULATION THAT UNDERSTANDS IT, ITS USE AND METHOD TO REDUCE IT IN A MAMMAL. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR005811A1 true AR005811A1 (en) | 1999-07-14 |
Family
ID=51929382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970100576A AR005811A1 (en) | 1997-02-13 | 1997-02-13 | MODIFIED NATURAL COMPLEMENTARY VIA PROTEIN, SEQUENCE AND DNA CONSTRUCTION THAT CODES IT, CONJUGATED AND PHARMACEUTICAL FORMULATION THAT UNDERSTANDS IT, ITS USE AND METHOD TO REDUCE IT IN A MAMMAL. |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR005811A1 (en) |
-
1997
- 1997-02-13 AR ARP970100576A patent/AR005811A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9509172A (en) | Native complement pathway protein DNA sequence construction of conjugated dna use of a process protein to reduce complement pathway protein in a mammal and pharmaceutical formulation | |
| AR009436A1 (en) | A FC-OB FUSION PROTEIN, A NUCLEIC ACID SEQUENCE THAT CODES IT, A VECTOR, PREPARATION PROCEDURE, PHARMACEUTICAL COMPOSITIONS AND USES. | |
| EA199800946A1 (en) | CONCENTRATED ANTIBODY PREPARATION | |
| AR038568A1 (en) | ANTI-A BETA ANTIBODIES AND ITS USE | |
| AR030760A1 (en) | NEW RECEIVER NUCLEIC ACIDS AND POLYPEPTIDES | |
| ES2165851T3 (en) | MULTIVALENT PROTEINS THAT JOIN ANTIGENS. | |
| BR9808881A (en) | Compounds for prostate cancer immunotherapy and methods for their use | |
| ES2149149T1 (en) | INTERLEUKIN-18 FIXING PROTEINS, THEIR PREPARATION AND USE. | |
| ES2139012T3 (en) | PEPTIDES OF HUMAN P53 PROTEIN INTENDED FOR USE IN COMPOSITIONS THAT INDUCE A REACTION IN HUMAN T-LYMPHOCYTES, AND SPECIFIC T-CYTOTOXIC T-LYMPHOCYTES. | |
| ES2185705T3 (en) | BIFUNCTIONAL PROTEIN, PREPARATION AND USE. | |
| HUP0002831A3 (en) | Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods | |
| PA8426301A1 (en) | HUMAN BIKUNINA | |
| CY1105895T1 (en) | SOLUBLE INTEPLEUKIN-6 RECEPTOR/BINDER CHIMERIC PROTEIN, THEREOF AND USES THEREOF | |
| BR9816013A (en) | Interleukin-18 Binding Protein | |
| ES2194935T3 (en) | STABLE PREPARATIONS OF TRANSGLUTAMINASE AND PROCEDURE FOR PREPARATION. | |
| DE3672950D1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING THYMUS EXTRACT FACTIONS. | |
| DE69434384D1 (en) | METALKOMPLEXBILDNER | |
| ATE331728T1 (en) | PROTEIN LABELING WITH RADIOACTIVE PHOSPOR AND TARGETED RADIOTHERAPY | |
| AR006150A1 (en) | MODIFIED NATURAL COMPLEMENTARY VIA PROTEIN ABLE TO FORM A C3 CONVERTASE RESISTANT TO DOWNWARD REGULATION, DNA SEQUENCES THAT CHANGE SUCH PROTEIN, USES OF SUCH PROTEIN AND COMPOSITIONS CONTAINING IT | |
| ES2061521T3 (en) | PROTEINS WITH GLUTATION-S-TRANSFERASE ACTIVITY, DNA SEQUENCES, ANTIBODIES, POXVIRUSES AND MEDICINES FOR THE PREVENTION OF EQUISTOSOMIASIS. | |
| MX9703364A (en) | PEPTIDES CAPABLE OF BINDING THE SH3 DOMAIN OF GAP PROTEIN, NUCLEOTIDIC SEQUENCES CODING FOR THESE PEPTIDES, THEIR PREPARATION AND USE. | |
| AR005811A1 (en) | MODIFIED NATURAL COMPLEMENTARY VIA PROTEIN, SEQUENCE AND DNA CONSTRUCTION THAT CODES IT, CONJUGATED AND PHARMACEUTICAL FORMULATION THAT UNDERSTANDS IT, ITS USE AND METHOD TO REDUCE IT IN A MAMMAL. | |
| ATE141415T1 (en) | CONJUGATES OF ANTIBODIES WITH VARIABLE DOMAIN | |
| PT1007717E (en) | PROCESSES AND COMPOSITIONS FOR CANCER THERAPIES, USING GENES THAT CODE THE BETA INTERFERENCE | |
| DK1165102T3 (en) | Matrix protein preparations for grafting in non-mineralized tissue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |